Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05644925
Other study ID # PiCSO-STEMI
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2024
Est. completion date February 2026

Study information

Verified date February 2023
Source Fundacio Privada Mon Clinic Barcelona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study we pretend to determine the molecular (miRNAs expression, angiogenic and inflammatory biomarkers) and microcirculatory (assessed by the innovative continuous intracoronary thermodilution technique) effects of PiCSO compared to a standard PCI control group in patients with high-risk anterior STEMI. Then, we aim to assess the efficacy of these molecular biomarkers as prognostic tools. Also, we will evaluate the impact of PiCSO on the coronary microcirculation beyond the acute phase in the follow-up six months after STEMI. Finally, we will assess PiCSO influence on Heart Failure (HF) clinical variables and patients' quality of life including a cost-effectiveness assessment in the mid-term follow-up one year after the STEMI event.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date February 2026
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old. 2. Anterior STEMI (ECG with persistent elevation = 2 mm (0.2 mV) in 2 or more contiguous anterior precordial leads (V2, V3, V4) in men or = 1.5 mm (0.15 mV) in women. 3. Culprit lesion in proximal or mid Left Anterior Descending Artery (LAD). 4. Pre-PCI TIMI flow 0-1. 5. Symptoms consistent with myocardial ischemia (persistent chest pain, dyspnea, nauseas/vomiting, fatigue, palpitations or syncope) present for = 12 hours. 6. The patient is eligible for primary PCI. 7. Informed consent received and signed for study enrollment. Exclusion Criteria: 1. Contraindication to coronary angiogram or PCI. 2. Implants or foreign bodies in the coronary sinus. 3. Known allergies to polyurethanes, Polyethylene Terephthalate (PET) or stainless steel. 4. Known pregnancy or breastfeeding. 5. Known coagulopathy. 6. Known severe kidney disease (eGFR <=30 mL/min/1.73) and/or hemodialysis. 7. Known large pericardial effusion or cardiac tamponade. 8. Central hemodynamically relevant left-right shunt. 9. Previous MI or Coronary Artery Bypass Graft (CABG). 10. Previous history of stroke, transient ischemic attack (TIA) or reversible ischemic neurological deficit within last 6 months. 11. Cardiopulmonary resuscitated (CPR) cardiac arrest = 5 minutes whom baseline neurologic status is not present. 12. Unconscious at presentation. 13. Need for circulatory support. 14. Need for invasive mechanical ventilation. 15. Need for temporal intravenous pacemaker. 16. Patient not suitable for femoral access. 17. Known contraindication for adenosine administration (severe asthma, complicated Atrioventricular (AV) block, critical aortic stenosis, severe cardiac arrhythmias, severe valve diseases). 18. Known epicardial stenosis greater than 50% distal to the culprit LAD lesion. 19. Active participation in another drug or device investigational trial. 20. Medical, social or psychological condition that limits the ability of patient to participate in the study. 21. Patients with definite or probable coronavirus disease 19 diagnosis within 2 weeks prior to STEMI.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PiCSO Impulse System
The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
Procedure:
Percutaneous Coronary Intervention (PCI)
Minimally invasive procedures used to open clogged coronary arteries

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Fundacio Privada Mon Clinic Barcelona Miracor Medical SA

Outcome

Type Measure Description Time frame Safety issue
Primary Superiority of PiCSO in reducing microvascular dysfunction To determine the superiority of PiCSO in reducing the microvascular dysfunction (defined as microvascular resistance >500 WU) as compared to standard of care After primary PCI at time 0 after intervention
See also
  Status Clinical Trial Phase
Completed NCT03579914 - Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients N/A
Withdrawn NCT02502747 - RIGENERA 2.0 Trial Phase 2